Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8791707 | 0.91 | MEN1 (0.61) | MEN1KMT2AKDM4ELMNACHRM5 | |
| SCHEMBL19554727 | 0.90 | MEN1 (0.68) | MEN1KMT2AKDM4EGAALMNA | |
| SCHEMBL2262428 | 0.89 | MEN1 (0.67) | MEN1KMT2AKDM4EGAALMNA | |
| Hydrochloric Acid SCHEMBL28528536 | 0.89 | MEN1 (0.67) | MEN1KMT2AKDM4EGAALMNA | |
| SCHEMBL6061686 | 0.88 | MEN1 (0.86) | MEN1KMT2AKDM4EGAALMNA | |
| SCHEMBL29764514 | 0.88 | MEN1 (0.86) | MEN1KMT2AKDM4EGAALMNA | |
| SCHEMBL3560864 | 0.84 | POLB (0.61) | MEN1KMT2AKDM4EHTTPKM | |
| SCHEMBL6061687 | 0.83 | MEN1 (0.78) | MEN1KMT2AKDM4EGAALMNA | |
| SCHEMBL28694741 | 0.83 | MEN1 (0.73) | MEN1KMT2AKDM4EGAALMNA | |
| Hydrochloric Acid SCHEMBL4713610 | 0.83 | POLB (0.60) | MEN1KMT2AKDM4EHTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1543005-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1440071-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | Pfizer Japan Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026869-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | MEN1 4812/4885KMT2A 3423/4885KDM4E 2141/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | MEN1 3931/4885KMT2A 2579/4885KDM4E 1539/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | MEN1 4817/4885KMT2A 3296/4885KDM4E 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.